March 31, 2020 | London

The Future of Pharma: Bringing Cell & Gene Therapies to Scale

Ground-breaking innovations are upending medicine every day, as new technologies, treatments and therapies are developed. Gene therapy holds the potential to revolutionize healthcare as we know it, offering new solutions to illnesses that defied existing treatment plans. Beyond the obvious patient implications, the field is also poised to be a strong growth opportunity for the biotech and pharmaceutical sectors. In this special briefing event, Bloomberg will convene the leaders and experts shaping the future of gene therapy for a conversation on the benefits and risk factors that will affect the regulation, manufacturing and application of these therapies as stakeholders work to bring them to scale. This event will discuss bringing regenerative medicine, cell therapy and IPSCs to scale. 


March 31 - Tuesday

8:00 am

Registration & Networking Breakfast

9:00 am

Welcome Remarks


9:05 am

Opening Remarks


  • Toshikazu Ban

    Corporate Vice President, Deputy General Manager, Pharmaceuticals, FUJIFILM Corporation

9:10 am

The Challenge of Scale

With the goal of gene therapy to address disease at a genetic level, this has meant that demand for these products to treat a wider array of illnesses has grown. The question of how to effectively manufacture individualized, personal therapies for small and large patient populations is key. We’ll hear from executives who will discuss the ways in which businesses are working to scale this technology using a sustainable business model.



9:45 am

A Cellular Analysis of Gene Therapy

In conversation with: Dave Lennon, President of Novartis AveXis and James Paton, Health Reporter for Bloomberg News discuss the highlights of the gene therapy market. This promises to be a riveting conversation, that will outline some of the opportunities and challenges within pharmaceutical sector.



10:10 am

Bloomberg Intelligence Presentation on Gene Therapy


10:25 am

Investment in Gene Therapy

Beyond manufacturing, investment within this sector is on the rise and understanding the growth areas is key, if companies are to spend money in this arena. Our panel will discuss the key investment areas and the market potential of this exciting new technology. We will also be discussing the questions around paying for treatments and the regulatory side of the industry, which are vital when looking at the market potential and opportunities that exist within this unique sector.



11:00 am

Closing Remarks


James Paton

Health Reporter Bloomberg News

Toshikazu Ban

Corporate Vice President, Deputy General Manager, Pharmaceuticals FUJIFILM Corporation

John Lauerman

Health Reporter Bloomberg News

John Dawson

Chief Executive Officer Oxford Biomedica

Christine Günther

CEO Apceth Biopharma

Andy Topping

Chief Scientific Officer Fujifilm Diosynth Biotechnologies

Tony Wood

Senior Vice President and Head of Medicinal Science and Technology GSK

Dave Lennon

President of AveXis Novartis

Cinney Zhang

Equity Research Analyst Bloomberg Intelligence

Michael Shah

Equity Research Analyst Bloomberg Intelligence

Meindert Boysen

Director, Centre for Health Technology Evaluation National Institute for Health and Care Excellence (NICE)

Nicola Heffron

European Senior Vice President BlueBird Bio

Dmitry Kuzmin

Founder and Managing Partner 4BIO Capital

Naveed Siddiqi

Partner Novo Holdings


For over 80 years, Fujifilm has relied on innovation and leading-edge proprietary technologies to build a vast portfolio of products across a broad spectrum of industries from photography to biopharmaceuticals to medical diagnostics and devices. Every diagnostic instrument and utility, pharmaceutical product, or regenerative therapy we develop plays a particular role in the care pathway with an eye toward total healthcare covering prevention, diagnosis and treatment.